This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Nagasawa, K Articles by Ohta, A Search for Related Content PubMed PubMed Citation Articles by Nagasawa, K Articles by Ohta, A Social Bookmarking                         What's this?

Prevention of steroid-induced osteonecrosis of femoral head in systemic lupus erythematosus by anti-coagulant

Department of Internal Medicine, Saga Medical School, Japan, nagasak{at}post.saga-med.ac.jp

Y Tada

Department of Internal Medicine, Saga Medical School, Japan

S Koarada

Department of Internal Medicine, Saga Medical School, Japan

H Tsukamoto

Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Japan

T Horiuchi

Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Japan

S Yoshizawa

Internal Medicine, Munakata Medical Association Hospital, Japan

K Murai

Second Department of Internal Medicine, Miyazaki Medical College, Japan

A Ueda

Internal Medicine, Miyazaki Prefectural Hospital, Japan

Y Haruta

Department of Internal Medicine, Saga Medical School, Japan

A Ohta

Department of Nursing, Saga Medical School, Japan

Although osteonecrosis of femoral head (ONF) is one of the serious complications in systemic lupus erythematosus (SLE) associated with corticosteroid therapy, there has been few trials of prevention of ONF described. We aimed to prevent ONF in steroid-treated SLE patients using anticoagulant, warfarin, conducting a multicenter prospective study. Sixty newly diagnosed SLE patients requiring 40 mg/day or more prednisolone were alternately assigned to either of two groups; a warfarin group and a control one. Warfarin (1 5 mg/day) was started together with the beginning of steroid therapy and continued at least for three months. Patients were observed for the development of silent ONF by magnetic resonance imaging (MRI) and symptomatic ONF by plain radiography for over five years. The warfarin group consisted of 31 patients (62 hips) and the control one 29 patients (58 hips). Silent ONF developed in 13 hips (21%) and 19 hips (33%) in the warfarin group and the control group, respectively (P = 0.13). On the other hand, warfarin tended to prevent symptomatic ONF; only three hips of 62 (4.8%) in the warfarin group and eight hips of 58 (14%) in the control group (P = 0.08) developed silent ONF. It was also found that silent ONF developed, if it did, very early; within three months in 16 of 18 patients (89%). Among risk factors for silent ONF, steroid pulse therapy was most outstanding and it seemed to overcome the effect of warfarin. Taken together, for the time being, anticoagulant therapy, if not significantly sufficient, may be of use for the prevention of steroid-induced ONF in SLE. We consider that this study added to important evidence for the pathogenesis and prevention of ONF.

Key Words: osteonecrosis of femoral head • SLE • warfarin • corticosteroid • clinical trial

Lupus, Vol. 15, No. 6, 354-357 (2006)
DOI: 10.1191/0961203306lu2311oa


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				T. Asada, T. Kushida, M. Umeda, K. Oe, H. Matsuya, T. Wada, K. Sasai, S. Ikehara, and H. Iida Prevention of corticosteroid-induced osteonecrosis in rabbits by intra-bone marrow injection of autologous bone marrow cells Rheumatology, May 1, 2008; 47(5): 591 - 596. [Abstract] [Full Text] [PDF]